Early treatment check for high-risk CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed CLL or SLL diagnosis within the last 18 months.
- Your leukemia is “high-risk,” based on test results like CLL-IPI score 4+ and/or 3+ chromosome abnormalities.
- You had specific cancer genetics tests (FISH and possibly TP53 and IgVH gene tests) done within required time windows before enrolling.
- You have not started any CLL/SLL treatment yet, and you do not currently meet criteria for needing active CLL therapy.
- You meet several “health readiness” tests: age 18+, good enough blood counts, heart/liver/kidney function, and you can take pills by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests a combination of three drugs (epcoritamab, venetoclax, and ibrutinib) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have changes in the TP53 gene. The goal is to see if this combination can effectively treat the disease in patients who have not had prior therapy.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.